Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS ReST Committee
Description
On this episode, Dr. Murray welcomes Andre Witkin, MD, Associate Professor, Tufts University School of Medicine, Boston, MA, to discuss the article, Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee.
On February 17, 2023, pegcetacoplan 15mg (Syfovre – Apellis Pharmaceuticals, Waltham MA) was approved by the US Food and Drug Administration (FDA) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Beginning in April 2023, the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee began receiving reports of intraocular inflammation (IOI) following intravitreal pegcetacoplan administration. In addition to cases of IOI without retinal vascular involvement, several reported cases included retinal vasculitis resulting in occlusive retinal vasculopathy and significant vision loss. The American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee, as well as an expert panel, performed a retrospective review of cases of retinal vasculitis reported to the ASRS. Clinical and imaging characteristics were reviewed for evidence of retinal vasculitis and analyzed.
For more information visit www.ASRS.org/JVRDForum.
Welcome to ASRS’s Journal of Vitreoretinal Diseases (JVRD) Author’s Forum. JVRD is the official scientific peer-reviewed journal of the American Society of Retina Specialists (ASRS) offering the highest quality and most impactful research and clinical information in the field. Join host Dr. Timothy Murray, Editor-in-Chief for JVRD as he discusses cutting-edge developments featured in JVRD with the lead authors who share clinical pearls and explore their significance for advancing patient care.
Audio episodes are available on Amazon Music, Apple Podcasts, Google Podcasts, Spotify and other podcast directories.
United States
